Anteris Technologies Global Corp. (NASDAQ:AVR) Stock Has Consensus Price Target of $14.00

Shares of Anteris Technologies Global Corp. (NASDAQ:AVR) have been assigned a consensus recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $14.00.

A number of equities research analysts have commented on AVR shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Finally, Barclays raised shares of Anteris Technologies Global to a “hold” rating in a research report on Wednesday, October 7th.

Anteris Technologies Global Trading Down 4.9%

AVR opened at $6.05 on Monday. Anteris Technologies Global has a 12-month low of $3.30 and a 12-month high of $11.06. The business’s fifty day simple moving average is $8.18 and its 200-day simple moving average is $8.05. The company has a market capitalization of $589.63 million, a price-to-earnings ratio of -3.10 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR) last announced its earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The company had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. During the same period last year, the business posted ($0.58) EPS. On average, equities research analysts predict that Anteris Technologies Global will post -1.21 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder L1 Capital Pty Ltd bought 272,695 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were bought at an average price of $7.18 per share, with a total value of $1,957,950.10. Following the transaction, the insider owned 6,358,271 shares in the company, valued at approximately $45,652,385.78. This trade represents a 4.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have purchased 1,554,730 shares of company stock worth $11,694,513 and have sold 3,008,459 shares worth $25,243,576. Corporate insiders own 4.50% of the company’s stock.

Hedge Funds Weigh In On Anteris Technologies Global

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Anteris Technologies Global during the second quarter worth about $56,846,000. Bank of New York Mellon Corp acquired a new position in Anteris Technologies Global in the 2nd quarter worth approximately $2,292,000. ADAR1 Capital Management LLC purchased a new position in Anteris Technologies Global during the 2nd quarter worth approximately $30,979,000. Perceptive Advisors LLC raised its position in Anteris Technologies Global by 104.4% during the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after buying an additional 1,750,000 shares during the last quarter. Finally, Militia Capital Management LLC purchased a new position in Anteris Technologies Global during the 1st quarter worth approximately $3,358,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.